Abstract
Summary
The Lysosomal Storage Disease Partnering 2007-2012 report provides
understanding and access to the lysosomal storage disease partnering deals and
agreements entered into by the worlds leading healthcare companies.
Trends in lysosomal storage disease partnering deals Top lysosomal storage
disease deals by value Deals listed by company A-Z, industry sector, stage of
development, technology type
Description
Lysosomal Storage Disease Partnering 2007-2012 provides understanding
and access to the lysosomal storage disease partnering deals and agreements
entered into by the worlds leading healthcare companies.
The report provides an analysis of lysosomal storage disease partnering deals.
The majority of deals are discovery or development stage whereby the
licensee obtains a right or an option right to license the licensors lysosomal
storage disease technology. These deals tend to be multicomponent, starting
with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals
terms provides critical insight into the negotiation process in terms of what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases do not.
This data driven report contains over 20 links to online copies of actual
liver disease deals and contract documents as submitted to the Securities
Exchange Commission by companies and their partners, where available. Contract
documents provide the answers to numerous questions about a prospective
partner's flexibility on a wide range of important issues, many of which will
have a significant impact on each party's ability to derive value from the
deal.
The initial chapters of this report provide an orientation of lysosomal
storage disease partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an
overview of the trends in lysosomal storage disease partnering since 2007,
including a summary of deals by industry sector, stage of development, deal
type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading lysosomal storage disease deals
since 2007. Deals are listed by headline value, signed by bigpharma, most
active bigpharma. Where the deal has an agreement contract published at the
SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of lysosomal storage disease
partnering deals signed and announced since 2007. The chapter is organized by
company A-Z, stage of development at signing, deal type (collaborative R&D,
co-promotion, licensing etc), and technology type. Each deal title
links via Weblink to an online version of the deal record, and where available
the contract document, providing easy access to each contract document on
demand.
In conclusion, this report provides everything a prospective dealmaker needs
to know about partnering in the research, development and commercialization of
lysosomal storage disease technologies and products.
Report scope
Lysosomal Storage Disease Partnering 2007-2012 is intended to provide
the reader with an in-depth understanding and access to lysosomal storage
disease trends and structure of deals entered into by leading companies
worldwide.
This data driven report includes:
Trends in lysosomal storage disease dealmaking in the biopharma industry since
2007 Access to summary headline, upfront, milestone and royalty data The
leading lysosomal storage disease deals by value since 2007
In Lysosomal Storage Disease Partnering 2007-2012, the available deals
are listed by:
Headline value Upfront payment value Royalty rate value Company A-Z Industry
sector Stage of development at signing Deal component type Technology type
Each deal title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each contract
document on demand.
Benefits
Lysosomal Storage Disease Partnering 2007-2012 provides the reader with
the following key benefits:
- In-depth understanding of lysosomal storage disease deal trends since 2007
- Access to summary headline, upfront, milestone and royalty data
- Comprehensive access to over 20 actual lysosomal storage disease deals
entered into by the world's biopharma companies since 2007
- Insight into key deal terms included in contracts, where disclosed
- Understand the key deal terms companies have agreed in deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in lysosomal storage disease partnering
- 2.1. Introduction
- 2.2. Lysosomal storage disease partnering over the years
- 2.3. Bigpharma lysosomal storage disease dealmaking activity
- 2.4. Lysosomal storage disease partnering by deal type
- 2.5. Lysosomal storage disease partnering industry sector
- 2.6. Lysosomal storage disease partnering by stage of development
- 2.7. Lysosomal storage disease partnering by technology type
- 2.8. Disclosed financial deal terms for lysosomal storage disease
partnering
- 2.8.1 Lysosomal storage disease headline values
- 2.8.2 Lysosomal storage disease upfront payments
- 2.8.3 Lysosomal storage disease milestone payments
- 2.8.4 Lysosomal storage disease royalty rates
Chapter 3 - Leading lysosomal storage disease deals
- 3.1. Introduction
- 3.2. Top lysosomal storage disease deals by value
- 3.3. Top lysosomal storage disease deals involving bigpharma
Chapter 4 - Dealmaking directory
- 4.1. Introduction
- 4.2. Company A-Z
- 4.3. By deal type
- Asset purchase
- Bigpharma outlicensing
- Co-development
- Collaborative R&D
- Co-market
- Contract service
- Co-promotion
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Settlement
- Spin out
- Sub-license
- Supply
- Termination
- 4.4. By industry sector
- Academic
- Bigpharma
- Biotech
- Drug delivery
- Medical device
- Diagnostic
- Generic pharma
- Government
- Non-profit
- Pharmaceutical
- Research tools
- Services
- Specialty pharma
- 4.5. By stage of development
- Discovery
- Pre-clinical
- Phase I
- Phase II
- Phase III
- Registration
- Marketed
- 4.6. By technology type
- Analysis
- Animal models
- Assays
- Bioinformatics
- Biological compounds
- Biomarkers
- Biomaterials
- Cell culture
- Cell therapy
- Clinical testing
- Diagnostic - companion
- Devices
- Diagnostics
- Discovery tools
- DNA probes
- Drug delivery
- Enabling technology
- Epigenetics
- Equipment
- Facilities
- Gene therapy
- Genomics
- Imaging
- Industrial chemicals
- In vitro models
- Monoclonal antibodies
- Nanotechnology
- Oligonucleotide
- Peptides
- Personalised medicine
- Processes
- Proteomics
- Radio/Chemo-therapy
- Recombinant DNA
- Research services
- Research supplies
- RNA therapeutics
- Screening
- Small molecules
- Stem cells
- Vaccines
Chapter 5 - Partnering resource center
- 5.1. Online partnering
- 5.2. Partnering events
- 5.3. Further reading on dealmaking
Appendices
- Appendix 1 - Deal type definitions
- About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent titles from CurrentPartnering
- Order Form - Reports
Table of figures
- Figure 1: Lysosomal storage disease partnering since 2007
- Figure 2: Bigpharma - top 50 - lysosomal storage disease deals 2007 to 2011
- Figure 3: Bigpharma lysosomal storage disease deal frequency - 2007 to 2011
- Figure 4: Lysosomal storage disease partnering by deal type since 2007
- Figure 5: Lysosomal storage disease partnering by industry sector since
2007
- Figure 6: Lysosomal storage disease partnering by stage of development
since 2007
- Figure 7: Lysosomal storage disease partnering by technology type since
2007
- Figure 8: Lysosomal storage disease deals with a headline value
- Figure 9: Lysosomal storage disease deals with upfront payment values
- Figure 10: Lysosomal storage disease deals with milestone payments
- Figure 11: Lysosomal storage disease deals with royalty rates, %
- Figure 12: Top lysosomal storage disease deals by value since 2007
- Figure 13: Top lysosomal storage disease deals signed by bigpharma value
since 2007
- Figure 14: Online partnering resources
- Figure 15: Forthcoming partnering events
- Figure 16: Deal type definitions
Lysosomal Storage Disease Partnering 2007-2012 published by Current Partnering, a division of Wildwood Ventures Limited. This report consists of 150 pages and the price starts from US $ 995.
